MEREO BIOPHARMA GROUP PLC Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of -GBP 14.05 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-09-07.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2023-09-07
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 6 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month as first filed |
|---|---|---|---|
| 2023-06-30 | -14.05M GBP 6-K · filed 2023-09-07 | ||
| 2022-12-31 | -38.11M GBP 20-F · filed 2023-03-28 | ||
| 2022-06-30 | -18.12M GBP 6-K · filed 2023-09-07 | ||
| 2021-12-31 | 71.99M GBP 20-F · filed 2023-03-28 | ||
| 2021-06-30 | 87.91M GBP 6-K · filed 2022-11-02 | ||
| 2020-12-31 | 7.89M GBP 20-F · filed 2023-03-28 | ||
| 2020-06-30 | 40.10M GBP 6-K · filed 2021-11-02 | ||
| 2019-12-31 | -8.35M GBP 20-F · filed 2022-03-31 | ||
| 2019-06-30 | 2.98M GBP 6-K · filed 2020-09-29 | ||
| 2018-12-31 | -24.96M GBP 20-F · filed 2021-03-31 | -24.96M GBP 20-F/A · filed 2019-05-29 | |
| 2017-12-31 | -2.15M GBP 20-F · filed 2020-06-15 | -2.15M GBP 20-F/A · filed 2019-05-29 | |
| 2016-12-31 | 39.07M GBP 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |